Global Respiratory Diagnostics Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Respiratory Diagnostics Market Size

• The global respiratory diagnostics market size was valued at USD 9.39 billion in 2024 and is expected to reach USD 17.37 billion by 2032, at a CAGR of 8.00% during the forecast period
• This growth is driven by factors such as growing incidence rate of respiratory diseases disorders globally

Respiratory Diagnostics Market Analysis

• Respiratory diagnostics are critical tools used for the detection, monitoring, and management of respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), lung infections, and pulmonary fibrosis. These tests include imaging, spirometry, molecular diagnostics, and blood gas analysis
• The rising prevalence of chronic respiratory diseases, increasing air pollution levels, and technological advancements in diagnostic devices are key drivers propelling the respiratory diagnostics market forward
• North America is dominating the respiratory diagnostics market with the largest market share of, 35.90%, driven by its advanced healthcare infrastructure, widespread availability of diagnostic services, and early adoption of innovative testing technologies
• Asia-Pacific is expected to witness the highest growth rate in the respiratory diagnostics market, driven by growing awareness of respiratory health, expanding middle-class populations, and government-led healthcare reform initiatives
• The imaging tests segment is expected to dominate the market with the largest market share of 68.44%, due to the increasing prevalence of chronic diseases, rising demand for non-invasive diagnostic techniques, and continuous advancements in imaging technologies such as MRI, CT, and ultrasound

Report Scope and Respiratory Diagnostics Market Segmentation    

Respiratory Diagnostics Market Trends

“Integration of Artificial Intelligence (AI) in respiratory diagnostic Tools”

• A growing trend in the respiratory diagnostics market is the integration of AI and machine learning algorithms in pulmonary function testing, chest imaging interpretation, and diagnostic decision support
• AI enables enhanced image analysis, anomaly detection, and automated reporting, which significantly improves diagnostic accuracy and reduces clinician workload
  • For instance, in April 2024, Medtronic announced its collaboration with NVIDIA to incorporate AI-driven imaging diagnostics into its portable spirometry solutions, enabling real-time analysis and earlier detection of pulmonary diseases
• This technological advancement is expected to revolutionize respiratory diagnostics by offering faster, more precise, and scalable solutions for disease screening and monitoring

Respiratory Diagnostics Market Dynamics

Driver

“Increasing Prevalence of Respiratory Diseases Due to Air Pollution and Lifestyle Factors”

• Rising air pollution levels, smoking rates, and exposure to occupational hazards are contributing to the increasing incidence of chronic respiratory diseases such as COPD, asthma, and bronchitis
• The rising number of affected individuals is prompting governments and healthcare systems to adopt more widespread and advanced diagnostic screening protocols
• In particular, urbanization and industrialization in developing nations are creating urgent needs for scalable respiratory diagnostic tools
  • For instance, in March 2024, the World Health Organization (WHO) reported a 12% increase in global COPD cases compared to 2020, citing poor air quality as a major contributing factor
• This widespread health burden is fueling demand for early detection tools, particularly spirometry and biomarker-based tests

Opportunity

“Surging Demand for Home-Based and Remote Respiratory Monitoring”

• With the shift toward decentralized care, there is growing demand for home-based respiratory monitoring tools that can help patients manage chronic conditions effective
• Telemedicine and remote patient monitoring platforms are incorporating portable spirometers and connected pulse oximeters, enhancing access to respiratory diagnostics outside traditional settings, This trend supports better long-term disease management, especially for elderly and immobile patients
  • For instance, in February 2024, Masimo launched a wireless respiratory rate and oxygen saturation monitoring kit designed for remote patient use, approved by the U.S. FDA for at-home care
• This opens lucrative growth avenues for companies offering user-friendly, connected diagnostic solutions for chronic respiratory patients

Restraint/Challenge

“Limited Access to Diagnostics in Low-Income and Rural Regions”

• Despite technological advancements, many rural and under-resourced areas face inadequate access to respiratory diagnostic services due to cost, lack of trained personnel, and insufficient infrastructure
• Transportation issues, scarcity of diagnostic labs, and low awareness levels further hinder timely disease detection and treatment.
• This results in underdiagnosis and delayed interventions, exacerbating health outcomes in vulnerable populations
  • For instance, in May 2024, a study published by The Lancet highlighted that 45% of rural clinics in sub-Saharan Africa lacked basic spirometry equipment, leading to misdiagnosis of chronic respiratory conditions
• Addressing these disparities requires targeted investment in mobile diagnostic units, public health programs, and affordable testing solutions

Respiratory Diagnostics Market Scope

The market is segmented on the basis of product and services, test type, diseases, end user, and distribution channel.

In 2025, the tuberculosis is projected to dominate the market with a largest share in diseases segment

The tuberculosis segment is expected to dominate the respiratory diagnostics market with the largest share of 32.12% in 2025 due to the high global prevalence of the disease and the increased availability of advanced diagnostic tools.

The imaging tests is expected to account for the largest share during the forecast period in test type segment

In 2025, the imaging tests segment is expected to dominate the market with the largest market share of 68.44%, due to the increasing prevalence of chronic diseases, rising demand for non-invasive diagnostic techniques, and continuous advancements in imaging technologies such as MRI, CT, and ultrasound.

Respiratory Diagnostics Market Regional Analysis

“North America Holds the Largest Share in the Respiratory Diagnostics Market”

• North America is dominating the respiratory diagnostics market with the largest market share of, 35.90%, driven by its advanced healthcare infrastructure, widespread availability of diagnostic services, and early adoption of innovative testing technologies
• The U.S. leads the region due to a high prevalence of respiratory diseases such as asthma, COPD, and pneumonia, along with supportive reimbursement policies and increased awareness for early disease detection
• Continuous investments in research and development, coupled with public-private partnerships, support sustained market expansion and product accessibility across urban and rural healthcare settings

“Asia-Pacific is Projected to Register the Highest CAGR in the Respiratory Diagnostics Market”

• Asia-Pacific is expected to witness the highest growth rate in the respiratory diagnostics market, driven by growing awareness of respiratory health, expanding middle-class populations, and government-led healthcare reform initiatives
• Countries such as China, India, Japan, and South Korea are emerging as key contributors, driven by rising air pollution, increased tobacco consumption, and a growing burden of chronic respiratory conditions
• China is heavily investing in healthcare infrastructure modernization, while India is scaling up the availability of point-of-care diagnostics and community health programs aimed at respiratory screening
• Japan's aging population and demand for precision diagnostics, along with Southeast Asia's integration of diagnostic services in infectious disease control programs, further enhance market momentum

Respiratory Diagnostics Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

The Major Market Leaders Operating in the Market Are:

• GENERAL ELECTRIC COMPANY (U.S.)
• Koninklijke Philips N.V. (Netherlands)
• Medtronic (Ireland)
• COSMED srl (Italy)
• F. Hoffmann-La Roche Ltd (Switzerland)
• NIHON KOHDEN CORPORATION (Japan)
• Drägerwerk AG & Co. KGaA (Germany)
• Bio-Rad Laboratories, Inc. (U.S.)
• GC Diagnostics Corporation (South Korea)
• Masimo (U.S.)
• bioMérieux SA (France)
• Carestream Health (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• Novartis AG (Switzerland)
• Abbott (U.S.)
• Johnson & Johnson Services, Inc. (U.S.)
• GSK plc (U.K.)
• Bayer AG (Germany)
• BD (U.S.)

Latest Developments in Global Respiratory Diagnostics Market

• In September 2024, Becton, Dickinson and Company (U.S.) completed the acquisition of Edwards Lifesciences Corporation's Critical Care product group, which has since been renamed BD Advanced Patient Monitoring, unlocking new value streams and strengthening BD’s portfolio of innovative connected care solutions
• In June 2024, bioMérieux (France) announced that its BIOFIRE SPOTFIRE Respiratory/Sore Throat (R/ST) Panel Mini received U.S. FDA Special 510(k) clearance along with a CLIA-waiver, enabling rapid multiplex PCR testing for five major respiratory and throat pathogens within approximately 15 minutes
• In January 2024, Wipro GE Healthcare a joint venture between GE Precision Healthcare LLC (U.S.) and Wipro Enterprises Limited (India) signed a memorandum of understanding (MoU) with the Indian Institute of Science (IISc) to advance healthcare innovation, research, and technology development in India
• In August 2023, Bio-Rad Laboratories, Inc. (U.S.) introduced two new products, PTC Tempo 48/48 and PTC Tempo 384, both designed to support PCR applications across basic research, translational science, process development, and quality control environments
• In May 2022, QuantuMDx Group Limited (U.K.), a leading provider of point-of-care diagnostics, launched its Q-POC SARS-CoV-2, Flu A/B & RSV Assay, a multiplex respiratory panel test designed to deliver rapid and accurate testing for respiratory viruses at the point of care
• In January 2022, Highmark Health and Bosch entered a strategic research partnership to develop AI-powered sensor technologies for detecting pediatric pulmonary conditions, such as asthma, building on traditional diagnostic practices with cutting-edge innovations

SKU-15122